Roflumilast | Astrazeneca | ||
500 mcg;Tablet, Oral |
Less Than $1000 mn
|
||
More Than 5
|
More Than 5
|
||
Less Than 5
|
None | ||
More Than 5
|
More Than 5
|
||
Indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. | |||
Yes
|
Daliresp | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 |
---|---|---|---|---|---|---|
****** | ******* | ******* | ******* | ******* | ******* | ******* |
******* | ******* | ******* | ******* | ******* | ******* | ******* |
***** | ******* | ******* | ******* | ******* | ******* | ******* |
Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
---|---|---|---|---|---|
****** | *** \ *** | *** **, **** | ******* | ******** | ******** ** *** **, **** |
******* | *** \ *** | *** **, **** | ******* | ******** | ******** ** *** **, **** |
***** | *** \ *** | *** **, **** | ******* | ******** | *** ****** ******* |